IRLAB Therapeutics AB

IRLAB A

SE0012675361

Pharmaceuticals

Market Closed - Nasdaq Stockholm Other stock markets 17:00:00 18/05/2026 BST			5-day change	1st Jan Change
1.268 ^SEK	+1.60%		+0.48%	-35.63%

05-06	IRLAB Q1 operating result swings to profit of SEK 10.7 mln	RE
05-06	Irlab reports growth in revenue and operating profit	FW

Irlab Secures Milestone Payment Following First Patient Dosed in Phase Ib Study with IRL757 for Parkinson's Disease

Published on 02/26/2026 at 11:00 am GMT

Finwire - Translated by Marketscreener - See original

IRLAB THERAPEUTICS AB

+1.60%

Irlab secures milestone payment after the first patient has been dosed in the Phase Ib study with IRL757 for Parkinson's disease.

Latest news about IRLAB Therapeutics AB

05-06	IRLAB Q1 operating result swings to profit of SEK 10.7 mln	RE
05-06	Irlab reports growth in revenue and operating profit	FW
05-06	IRLAB Therapeutics AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-05	Verisure climbs on earnings, OMXS30 index gains 1.2 percent	FW
05-05	Eight stocks hit new 52-week lows on the Stockholm Stock Exchange so far today	FW
05-05	Irlab launches SEK 68 million rights issue	FW
05-05	Irlab resolves on rights issue, obtains extended loan financing	RE
04-17	Christer Nordstedt Declines Re-Election as Board Member of IRLAB Therapeutics AB	CI
04-17	Irlab proposes two new board members; Chair to step down this autumn	FW
03-17	Irlab to present pirepemat data and AI platform at AD/PD conference	FW
03-04	Irlab Working to Secure Funding for Phase 3 Study of Mesdopetam - fc	FW
02-26	Study progress triggers $3 mln payment for IRLAB	RE
02-26	Stockholm Stock Exchange Rises for Third Consecutive Day, OMXS30 Index Up 0.3 Percent	FW
02-26	Stockholm Stock Exchange Climbs to New Record Highs, OMXS30 Index Rises 0.8 Percent	FW
02-26	Irlab Receives $3 Million Milestone Payment Following Dosing in Phase 1b Study	FW

IRLAB Therapeutics AB is a Sweden-based research and development company. It focuses on illnesses in the central nervous system and primarily on development of drugs to assist patients with Parkinsonâ€™s disease. The Company possesses a research platform Integrative Screening Process (ISP), which aims to discover and develop drug candidates for the treatment of brain diseases. The Company operates projects on both clinical phase and preclinical phases. The primary projects are IRL790 and IRL752, both on clinical phase. The IRL790 project is a psychomotor stabilizer for the treatment of levodopa (L-dopa) amino acid that dyskinesia induces in Parkinsonâ€™s Disease (PD-LIDs) and Parkinson Disease psychosis (PD-Psychosis). The IRL752 project aims at cortical enhancement for the treatment of Parkinson Disease Dementia (PD-D) and Behavioral and Psychological Symptoms of Dementia (BPSD).

Employees

Sector

Pharmaceuticals

Calendar

Earnings release - Q2 2026

More about the company